In today's episode, we take listeners on a deeper dive of specific details of FDA Emergency Use Authorizations: what they are, what they are not, how they are determined, specific nuances that they may subsequently enact, and how they are determined for approval. The topic is intended to be general around EUA’s, but COVID-19 specific examples are highlighted as well as those that have brought public attention to the EUA process.
Alexander H. Flannery, Pharm.D., FCCM, BCCCP, BCPS, is an Assistant Professor in the Department of Pharmacy Practice and Science at the University of Kentucky College of Pharmacy and a board certified critical care pharmacist in the medical ICU at University of Kentucky HealthCare.
Dr. Christopher R. Piszczatoski, PharmD, BCPS, is a clinical pharmacist working primarily in the ambulatory care field. Upon graduation from Auburn University’s Harrison School of Pharmacy, Dr. Piszczatoski completed a PGY-1 pharmacy residency at Putnam Community Medical Center in Palatka, Florida. From there, he obtained a fellowship with the University of Florida Colleges of Pharmacy and Medicine, and currently serves as the post-doctoral fellow embedded in family medicine. Dr. Piszczatoski’s practice interests include anticoagulation, diabetes management, transitions of care and telemedicine – for which he is currently leading initiatives to export these services to multiple pharmacy-naïve clinics.